A new shift register employing bottom-gate In-Ga-Zn-O thin-film transistors (IGZO TFTs) was proposed and fabricated. Depletion-mode IGZO TFTs were successfully turned off by employing two low-voltage-level signals. The IGZO shift register exhibited a high-voltage output pulse without any distortion and a maximum clock frequency of 417 kHz. The proposed shift register would be an important building block for a depletion-mode oxide TFT display.

Background This study aimed to evaluate whether fluvoxamine reduces clinical deterioration in adult patients with mild to moderate coronavirus disease 2019 (COVID-19), and to identify risk factors for clinical deterioration in patients admitted to a community treatment center (CTC). Materials and Methods A randomized, placebo-controlled trial was conducted in a CTC, in Seoul, Korea from January 15, 2021, to February 19, 2021. Symptomatic adult patients with positive results of severe acute respiratory syndrome coronavirus 2 real time-polymerase chain reaction within 3 days of randomization were assigned at random to receive 100 mg of fluvoxamine or placebo twice daily for 10 days. The primary outcome was clinical deterioration defined by any of the following criteria: oxygen requirement to keep oxygen saturation over 94.0%, aggravation of pneumonia with dyspnea, or World Health Organization clinical progression scale 4 or greater. Results Of 52 randomized participants [median (interquartile range) age, 53.5 (43.3 - 60.0) years; 31 (60.0%) men], 44 (85.0%) completed the trial. Clinical deterioration occurred in 2 of 26 patients in each group ( P >0.99). There were no serious adverse events in either group. Clinical deterioration occurred in 15 (6.0%) of 271 patients admitted to the CTC, and all of them were transferred to a hospital. In multivariate analysis, age between 55 and 64, fever and pneumonia at admission were independent risk factors for clinical deterioration. Conclusion In this study of adult patients with symptomatic COVID-19 who were admitted to the CTC, there was no significant differences in clinical deterioration between patients treated with fluvoxamine and placebo (ClinicalTrials.gov Identifier: NCT04711863 ).

In this study, a novel hybrid polyurethane/polycaprolactone (PU/PCL) tubular scaffold was fabricated using the electrospinning process for blood vessel prosthesis applications. The detailed microstructure and material properties such as porosity, tensile and bust strength, contact angle, and biocompatibility were investigated and compared with those of monolithic PU and PCL scaffolds. The mechanical properties of the hybrid PU/PCL scaffold (tensile strength: 18 MPa, pressure strength: 590 mmHg) were found to be within the range needed for artificial blood vessel applications. The pore sizes of the PU/PCL scaffold ranged from 5-150 um in diameter, are sufficient enough to allow nutrient diffusion across the membrane. The reduced hydrophobic property of the PU/PCL scaffold was the result of the addition of relatively less hydrophobic PU compared with monolithic PCL scaffold. The biocompatibility of the PU/PCL scaffold was evaluated through cytotoxicity testing, and morphological observation by scanning electron microscopy and confocal microscopy using cow pulmonary artery endothelial cells and fibroblast like cells (L929).

The LTC4S A(-444)C and CysLTR1 T(+927)C genotypes do not appear to be useful for predicting clinical responsiveness to montelukast, whereas bronchial hyperresponsiveness and total IgE appear to predict the degree of montelukast responsiveness in Korean asthmatic children with EIB.

No abstract

No abstract

PurposeThe purpose of this study was to investigate social and behavioral factors associated with prostate-specific antigen (PSA) screening in men in California, United States, who were over 40 years of age and had ever heard about PSA screening.Materials and MethodsThis survey was administered as a random-digit-dialing telephone survey to produce reliable estimates of medium-sized counties. It surveyed 42,000 households and interviewed 58,407 people randomly. It considered socioeconomic status and health behavior as affecting PSA screening. Access to health care was measured as having regular health care access. The main outcome measure was self-report of ever having undergone PSA screening at least once in the respondent's lifetime.ResultsOf 8,864 respondents, 82.2% were White, 7.7% were Latin, 4.2% were African American, and 5.9% were Asian. The respondents' mean age was 60.13 years. Age was the significant factor for PSA screening. Respondents aged 50-59 years were 3.5 times as likely to have undergone PSA screening as were those aged 40-49 years (OR=3.49, p≤0.001). Race was not statistically significant after considering other factors. People who had never married had statistically significantly lower screening than did people who were married (OR=0.71, p=0.001). Poverty levels were statistically significant in both the unadjusted and the adjusted analysis. People who had no regular health care access were much less likely to have undergone PSA screening than were people who had regular health care access (OR=0.22, p=0.001).ConclusionsThe likelihood of PSA screening was positively associated with increased age, marital status (married), higher socioeconomic status (higher federal poverty level and higher educational attainment), and health care access. However, there was no statistically significant association of PSA screening with race, employment, exercise, smoking, or drinking status.

No abstract